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Incidence 
According to the Sudden Cardiac Arrest 
Foundation (2014), each year, 424,000 
people in the U.S. (more than 1,000/day) 
experience EMS-assessed out-of-hospital 
non-traumatic sudden cardiac arrest.  This 
is roughly equivalent to the number of 
people who die from Alzheimers’ disease, 
assault with firearms, breast cancer, 
cervical cancer, colorectal cancer, 
diabetes, HIV, house fires, motor vehicle 
accidents, prostate cancer and 
suicides combined (Sudden Cardiac Arrest 
Foundation, 2014).  
It is estimated that the likelihood of 
surviving an out-of-hospital cardiac arrest 
(OHCA) to hospital discharge can be as 
low as 6% to 8% (Williams, Calder, Cocchi 
& Donnino, 2013). Additionally an 
estimated 200,000 hospitalized patients 
are treated for cardiac arrest annually. 
Adult inpatient cardiac arrest mortality 
rates have been historically high at 67% to 
71% despite advancement in resuscitation 
care (Williams et al., 2013). 
History 
The following is a historical timeline for 
the use of therapeutic hypothermia (TH) 
as described by Varnon and Acosta (2008): 
 Documented in 1803, Russians used 
a method of resuscitation that 
involved covering patients with snow 
hoping for return of spontaneous 
circulation (ROSC); 
 In 1813, TH was used in an effort to 
preserve injured limbs and for its 
numbing effects during amputations; 
 In 1937, Dr. Terry Fay “cooled” a 
patient to 32˚C for 24 hours to 
attempt to prevent cancer cells from 
multiplying; 
 In 1953, animal studies revealed 
heart and brain benefits of TH during 
cardiac surgery; 
 A direct link between body 
temperature and intracranial 
pressure and brain volume was 
documented in 1955. It was 
confirmed that TH reduced cerebral 
oxygen consumption, blood flow and 
metabolic rate in an animal brain; 
 By 1959, TH was used by 
neurosurgeons for head and spinal 
cord injuries as well as cardiac 
surgery; 
 Between 1960 and 1990, the use of 
TH decreased due to possible 
complications; 
 In 2002, the American Heart 
Association recommended TH as a 
treatment modality OHCA comatose 
victims of cardiac arrest. 
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Pathophysiology 
Hypoxic-ischemic Brain Injury 
The pathophysiology of brain injury following cardiac arrest is extremely complex. Due to the high 
metabolic demand, the brain is very susceptible to damage from deprivation of blood supply (Busl & Greer, 
2010).  Hypoperfusion to the brain initiates a cascade of events including (a) neuronal hyperexcitability-
excitotoxicity; (b) disrupted calcium hemostasis; (c) oxidative stress and free radical formation; (d) blood-
brain barrier dysfunction; (e) microvascular injury; (f) abnormal protease cascade; (g) cell death pathway 
signaling; and (h) postischemic inflammation (Williams et at., 2013).  
The initial injury happens at the time of insult but there may be continued damage after circulation and 
oxygenation are reestablished (Busl & Greer, 2010). Table 1 and Table 2 briefly describe the complex 
pathophysiological changes leading to cell damage following cardiac arrest and subsequent hypoxic-
ischemic brain injury, as described by Busl and Greer (2010).  
 
Table 1 
Biochemical mechanisms in hypoxic-ischemic brain injury 
Mechanism Immediate Effect Result 
Anoxic Depolarization ↓ extracellular sodium   
  ↓ extracellular calcium Activation of  
  ↑ intracellular calcium calcium-dependent processes 
ATP Depletion  Local acidosis Generalized acidosis, cell damage, 
edema 
Glutamate Release Excitotoxic activation of 
enzymes 
Neuronal tissue breakdown 
Free Radical formation, 
Nitric Oxide production 
  Cell breakdown 
Table 2 
Functional cell changes in hypoxic-ischemic injury 
Underlying Functional Problem Result 
Mitochondrial Damage Lack of energy repletion  
Cytoskeletal Damage Inability to maintain cell structure 
Glutamate Receptor Activation Immediate early gene up-regulation  
  Heat shock protein production 
Therapeutic Hypothermia (TH) 
Therapeutic hypothermia is the only intervention shown to improve neurological outcomes following 
cardiac arrest (Lantry, Dezman, & Hirshon, 2012). As described by Lantry, Dezman, and Hirshon (2012), 
hypothermia is subdivided into four stages: (1) mild hypothermia (32-35˚C) with physiological responses such 
as shivering and vasoconstriction; (2) moderate hypothermia (28-32˚C) marked by violent shivering, severe 
confusion, delirium and memory loss; (3) severe hypothermia (20-28˚C); and (4) profound hypothermia (less 
than 20˚C) both defined by cardiac dysrhythmias, shallow breathing and a progressive decline in consciousness 
that leads to death.  
Therapeutic hypothermia is characterized by mild hypothermia (32˚C to 34˚C). The body should be cooled 
to a core temperature of as soon as possible after ROSC. According to Sahuquillo & Vilalta (2007), the 
neuroprotective properties of TH are multifactorial and can include the following: 
i. Reduction in brain metabolic rate – all the energy-producing pathways in the brain including the cerebral 
metabolic rate for glucose, oxygen and lactate are reduced 2-4x by a 10°C decrease in temperature; 
ii. Effects on cerebral brain flow – the reduction in cerebral metabolic rate for oxygen results in a reduction 
of cerebral brain flow; 
iii. Reduction in critical threshold of oxygen delivery – by significantly lowering critical oxygen delivery with 
TH, the injured brain seems to be more tolerate of reduced levels of oxygen delivery without shifting to 
anaerobic metabolism; 
iv. Calcium antagonist – intracellular calcium overload has been associated with ischemia and neuronal 
death; 
v. Blockade of excitatory neurotransmitters – TH has been shown to reduce or block these excitotoxic 
neurotransmitters, such as glutamate, released by injured tissues that can lead to brain damage; 
vi. Decrease in edema formation – modulates the detrimental effects of injury on the blood brain barrier 
(BBB) by attenuating the increased permeability following injury and reduce protein passage into the brain, 
thus reducing edema ; 
vii. Modulation of inflammatory response – TH significantly reduces mediators of inflammatory cascades 
such as cytokines IL-6, IL-10, TNFα; 
viii. Neuroprotection of white matter – TH causes more profound neuroprotection than any known 
neuroprotective drug by protecting not only neuronal cell bodies but axons as well. 
Importance for Nursing 
Eligibility Criteria 
Table 3 describes the eligibility criteria for therapeutic hypothermia 
(Malhotra, Dhama, Kumar, & Jain, 2013). 
Table 3 
Eligibility Criteria for Therapeutic Hypothermia 
Inclusion Exclusion 
Initial rhythm of 
ventricular 
fibrillation (VF) or 
pulseless ventricular 
tachycardia (VT) 
Admission temperature ˂32˚C 
≤60 minutes from 
collapse to ROSC 
Evidence of neurological response to commands 
after resuscitation  
Systolic blood 
pressure (SBP) ˃90 
mmHg (or MAP ˃60 
mmHg) with no 
more than one 
vasopressor 
Cardiac arrest related to trauma 
Major head injury 
Systemic infection/sepsis 
Unconscious after 
successful ROSC 
with Glasgow Coma 
Scale ≤8 ˂6 h from 
ROSC 
  
  
  
  
Recent major surgery (within 14 days) 
Comatose state prior to cardiac arrest/coma from 
other causes 
Persistent hypotension (SBP ˂90 mmHg, MAP ˂60 
mmHg) despite one vasopressor for ˃30 minutes 
after ROSC  
Persistent hypoxemia SaO2 (arterial oxygen 
saturation) <85% after ROSC despite mechanical 
ventilation  
Pre-existing coagulopathy or bleeding 
“Do Not Resuscitate” or “Do Not Intubate” code 
status or terminal illness prior to cardiac arrest 
Initiation and Management 
During the induction phase, the goal is to reach the target core temperature 
of 32-34˚C as quickly as possible. A cooling rate of 1°C/h will reach a target 
temperature of 33°C in roughly 4 hours and is generally recommended 
(Alshimemeri, 2014).  
Patient monitoring should include: 
 electrocardiogram,  
 fluid balance, 
 invasive blood pressure measurement and 
 core body temperature measurement.  
Also, ongoing monitoring of lab values including  
 complete blood count,  
 platelet/coagulation, 
 electrolytes, and  
 arterial blood gas (Malhotra et al., 2013).  
Changes in body temperature leads to shifting of electrolytes in and out of 
the cell causing electrolyte abnormalities and risk for arrhythmias, therefor 
replacement should be administered during the induction phase and should be 
discontinued during rewarming (Malhotra et al., 2013).  
Sedatives, such as benzodiazepines, Propofol or short-acting narcotics, are 
used to reduce cerebral metabolism and with TH acts to reduce central nervous 
system (CNS) oxygen consumption (Malhotra et al., 2013).  
Shivering is common and can be managed with narcotics such as Fentanyl or 
a neuromuscular blockade if severe and impairs cooling (Malhotra et al., 2013). 
Invasive blood pressure and fluid balance monitoring is important due to 
hypotension and profuse diuresis that can result from TH (Malhotra et al., 2013). 
 
 
 
Importance for Nursing 
Table 4 
Adverse Effects 
Organ System Abnormality 
Renal Hypokalemia 
  Hypomagnesemia 
  Hypocalcemia, hypophosphatemia  
Endocrine Hyper/Hypoglycemia 
Cardiovascular Myocardial depression 
  Increased systemic vascular resistance (SVR) 
  Hypovolemia  
  Repolarization abnormalities  
  Bradyarrhythmias  
  Ventricular arrhythmias  
Gastrointestinal  Impaired gut motility/ileus 
  Hepatic dysfunction 
  Stress ulcer 
  Elevated serum amylase 
Respiratory Respiratory alkalosis  
  Reduced secretion clearance/cough 
Hematological  Impaired platelet function 
  Coagulopathy  
  Hemoconcentration  
Immunologic Neutropenia  
  Anti-inflammation 
Pharmacokinetics  Reduced clearance of sedatives and neuromuscular 
blockers 
Integumentary Poor wound healing 
Conclusion 
New methods of resuscitation and multidisciplinary goal-directed for post-
cardiac arrest patients has led to improved outcomes and a decrease in 
morbidity and mortality (Williams et al., 2013).  
The timing of the onset of cardiac arrest, start of CPR, ROSC, hospital arrival, 
initiation of TH, reaching target temperature and rewarming are all important 
factors in determining the post-arrest outcome (Shinada et al., 2013).  
European research reported by Nielsen et al., 2009 revealed over a period of 
4 years, half of 986 TH-treated OHCA patients survived and over >90% having 
good neurological outcomes at long-term follow-up. Therapeutic hypothermia 
has shown significant results that can greatly impact the outcome of such a 
devastating pathophysiological injury. 
Complications 
Table 4 briefly lists the possible adverse effects of therapeutic hypothermia as 
described by Malhotra et al. (2013).   
(Bard Medical, 2012) 
